Gene Jockeys: Life Science and the Rise of Biotech Enterprise

Rasmussen, Nicolas

ISBN 10: 142141340X / ISBN 13: 9781421413402

Edité par Johns Hopkins University Press, 2014

A propos de cet article

Acceptable condition. Reading copy. May have signs of wear and previous use scuffs, library copy, highlighting, writing, and underlining . May have foxing, slight water damage or tears. 100% GUARANTEE! Shipped with delivery confirmation. If you're not satisfied with purchase just return it!

N° de réf. du vendeur HSV.142141340X.A

Détails bibliographiques

• Titre: Gene Jockeys: Life Science and the Rise of Biotech Enterprise
• Éditeur: Johns Hopkins University Press
• Date de parution: 2014
• Langue: anglais
• ISBN à 10 chiffres: 142141340X
• ISBN à 13 chiffres: 9781421413402
• Reliure: Couverture rigide
• État de l'article: acceptable

A propos de ce titre

Synopsis

The scientific scramble to discover the first generation of drugs created through genetic engineering.

The biotech arena emerged in the 1970s and 1980s, when molecular biology, one of the fastest-moving areas of basic science in the twentieth century, met the business world. Gene Jockeys is a detailed study of the biotech projects that led to five of the first ten recombinant DNA drugs to be approved for medical use in the United States: human insulin, human growth hormone, alpha interferon, erythropoietin, and tissue plasminogen activator.

Drawing on corporate documents obtained from patent litigation, as well as interviews with the ambitious biologists who called themselves gene jockeys, historian Nicolas Rasmussen chronicles the remarkable, and often secretive, work of the scientists who built a new domain between academia and the drug industry in the pursuit of intellectual rewards and big payouts. In contrast to some who critique the rise of biotechnology, Rasmussen contends that biotech was not a swindle, even if the public did pay a very high price for the development of what began as public scientific resources. Within the biotech enterprise, the work of corporate scientists went well beyond what biologists had already accomplished within universities, and it accelerated the medical use of the new drugs by several years.

In his technically detailed and readable narrative, Rasmussen focuses on the visible and often heavy hands that construct and maintain the markets in public goods like science. He looks closely at how science follows money, and vice versa, as researchers respond to the pressures and potential rewards of commercially viable innovations. In biotechnology, many of those engaged in crafting markets for genetically engineered drugs were biologists themselves who were in fact trying to do science.

This book captures that heady, fleeting moment when a biologist could expect to do great science through the private sector and be rewarded with both wealth and scientific acclaim.

À propos de l'auteur

Nicolas Rasmussen is a professor of humanities at the University of New South Wales. His most recent book is On Speed: The Many Lives of Amphetamine.